ArticleCancer science2018

Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.

Yuka Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.